Launch of Gonax® 240 mg (New dosage form) in Japan for the treatment of prostate Cancer

TOKYO, June 17, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it launched Gonax® 240 mg (generic name: degarelix acetate, “Gonax®”) in Japan, a gonadotrophin-releasing hormone (GnRH) receptor antagonist, for the treatment of prostate cancer at 12-week intervals as the additional dosage and administration of Gonax®.

Gonax® is a GnRH receptor antagonist with a subcutaneously injectable formulation. Astellas acquired exclusive development and commercialization rights of Gonax® for the use of prostate cancer treatment in Japan from Ferring Pharmaceuticals in January 2006, and launched Gonax® for the indication of prostate cancer in Japan in October 2012. In January 2019, Astellas received approval for partial changes for the additional dosage and administration of Gonax® 480mg at 12-week intervals, and obtained manufacturing and marketing authorization for Gonax® 240 mg, in addition to the maintenance dose of Gonax® 80 mg at 4-week intervals.

GnRH is a hormone synthesized and released from the hypothalamus in the brain and is involved in the production of the male hormone testosterone thorough binding to the GnRH receptors in the pituitary gland. Although testosterone is an important hormone that plays a central role in the maintenance of male function, it also stimulates prostate cancer to grow and to spread out and in result, often aggravates symptoms in prostate cancer patients. Gonax® competitively inhibits the binding of GnRH to the GnRH receptors and controls the growth of prostate cancer by suppressing the testosterone.

Astellas believes that adding a new dosage and administration through the launch of Gonax® 240 mg will improve convenience for patients and reduce the burden on patients and further contribute to the treatment of prostate cancer.

Astellas reflected the impact from this launch in its financial forecasts of the current fiscal year ending March 31, 2020.
## Product overview

<table>
<thead>
<tr>
<th>Trade name (with additional underlined areas)</th>
<th>Gonax® 80 mg for Subcutaneous Injection, Gonax® 120 mg for Subcutaneous Injection, and Gonax® 240 mg for Subcutaneous Injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic name</td>
<td>Degarelix acetate</td>
</tr>
<tr>
<td>Indication</td>
<td>Prostate cancer</td>
</tr>
</tbody>
</table>

### Dosage and administration

Usually in adults, the starting-dose as degarelix is 240 mg which is administered as two subcutaneous injections of 120 mg each in two different abdominal regions. The second and subsequent doses of degarelix are administered at a maintenance-dose, starting four weeks after the starting-dose. For patients treated with every-four-week repeated doses, degarelix is administered at a maintenance-dose of 80 mg as one subcutaneous injection in one abdominal region. For patients treated with every-twelve-week repeated doses, degarelix is administered at a maintenance-dose of 480 mg as two subcutaneous injections of 240 mg each in two different abdominal regions.

- **Starting-Dose:**
  
  Add 3.0 mL of (JP) Water for Injection into a 120 mg vial of this product for one injection site. Administer one vial of this product immediately after reconstitution as a subcutaneous injection of 3.0 mL in the abdominal region. (Dissolution with 3.0 mL of water results in a drug concentration of 40 mg/mL.)

- **Every-four-week, Maintenance-dose Treatment:**
  
  Add 4.2 mL of (JP) Water for Injection into an 80 mg vial of this product. Administer one vial of this product immediately after reconstitution as a subcutaneous injection of 4.0 mL in the abdominal region. (Dissolution with 4.2 mL of water results in a drug concentration of 20 mg/mL.)

- **Every-twelve-week, Maintenance-dose Treatment:**
  
  Add 4.2 mL of (JP) Water for Injection into a 240 mg vial of this product for one injection site. Administer one vial of this product immediately after reconstitution as a subcutaneous injection of 4.0 mL in the abdominal region. (Dissolution with 4.2 mL of water results in a drug concentration of 60 mg/mL.)

### Date of approval*

January 8, 2019

### Date of NHI drug price listing*

May 29, 2019

### Date of Launch*

June 17, 2019

*Gonax® 240 mg for Subcutaneous Injection
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:
Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473